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Introduction
Our intestines are populated by trillions of bacteria, many of which 
are harmless commensals or even beneficial to our health. Howev-
er, some species are potentially harmful and can drive pathogen-
esis under certain conditions, e.g., in immune- deficient patients 
or upon epithelial barrier defects (1, 2). Although the intestinal 
immune system is adapted to cope with the high bacterial load in 
the intestinal lumen, dysfunction of immunoregulatory mecha-
nisms can result in an inadequate response to invading pathogens, 
or render the body hyperreactive toward harmless commensals 
and food antigens. Both events cause an increased susceptibility 
for (chronic) intestinal inflammation, as observed in inflammato-
ry bowel diseases (IBD) (1, 3).
Apart from changes in intestinal microbiota composition, 
genetic and environmental factors contribute to the risk of devel-
oping IBD (4, 5). Among the over 240 genetic risk loci that affect 
the susceptibility to develop IBD, a variant in the gene encoding 
protein tyrosine phosphatase non-receptor type 22 (PTPN22) (6) 
is of particular interest. This variant has been associated with 
an increased risk of developing a broad number of autoimmune 
disorders, including rheumatoid arthritis, systemic lupus erythe-
matodes, and type 1 diabetes (7–11), but protects from the onset 
of Crohn’s disease (CD) (6), one of the main subtypes of IBD. In 
contrast to other inflammatory disorders, which occur in organs 
that are typically sterile, IBD occurs in an organ with an excep-
tionally high bacterial load. This suggests that the protective 
effect of the PTPN22 variant observed in CD might result from 
an influence of bacteria, or bacteria-induced signaling cascades.
PTPN22 is exclusively expressed in immune cells (12) and acts 
as an important negative regulator of T and B cell activation (13), 
regulates type 1 as well as type 2 interferon signaling (14–16), and 
is involved in inflammasome activation (17). Further, we have pre-
viously shown that PTPN22 affects signaling pathways induced 
by the bacterial cell wall product muramyl-dipeptide (MDP), and 
loss of PTPN22 promotes autophagy, a cellular pathway not only 
involved in removing damaged proteins and organelles from the 
cytosol, but also essential for the clearance of invading bacteria 
(18). Defects in autophagy result in impaired goblet cell function 
(19, 20), and variants in genes involved in autophagy are associ-
ated with an enhanced risk of developing IBD (4, 21), underlining 
the role of autophagy in intestinal health. Despite its documented 
role in regulating pathways involved in bacterial handling, it is not 
known whether normal PTPN22 function is involved in shaping 
the composition of the intestinal microbiota. Since the microbi-
ota is importantly involved in IBD pathogenesis, we investigated 
here how presence of the disease-associated variant in PTPN22 
affects colitis development and consequently microbial composi-
tion in the intestine during health and disease.
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in our studies. Consistent with previous reports (14, 17), PTPN22–/– 
mice suffered from enhanced colitis in response to acute DSS 
treatment, while 619W mice were protected from disease onset 
(Supplemental Figure 1).
When PTPN22–/– and 619W mice were subjected to repeated 
DSS treatment, 619W mice were no longer protected from colitis 
induction. Although 619W mice lost significantly less weight during/
after the first DSS cycle, they showed weight development similar to 
that of their WT littermates in the second cycle, and after the third 
and fourth cycle they even revealed a delayed recovery when com-
pared with WT and PTPN22–/– mice (Figure 1A). Pronounced colitis 
in 619W mice upon 4 DSS cycles was also obvious in colonoscopy, 
and associated with pronounced colon shortening and increased his-
tology scores at the end of the experiment (Figure 1, B–D).
Results
Presence of the CD-associated variant in PTPN22 results in attenuat-
ed colitis upon acute DSS treatment, but results in enhanced chronic 
DSS-induced colitis. In order to understand how the autoimmunity- 
associated variant in PTPN22 affects the extent of intestinal 
inflammation, we subjected mice carrying either the WT or the dis-
ease-associated PTPN22 619W variant (the mouse ortholog of the 
human R620W variant, referred to as 619W mice) to acute dextran 
sulfate sodium–induced (DSS-induced) colitis (an overview of the 
timeline of the experiments and procedures can be found in Sup-
plemental Methods; supplemental material available online with 
this article; https://doi.org/10.1172/JCI123263DS1). Since the 
functional consequence of the PTPN22 variant is still a matter of 
debate (22), we also included PTPN22-deficient (PTPN22–/–) mice 
Figure 1. Presence of the 619W variant promotes chronic colitis. Chronic colitis was induced in PTPN22–/– and 619W mice as well as in their respective WT lit-
termates via administration of 4 cycles of DSS (1.5% DSS in the drinking water for 7 days, followed by 10 days recovery, each cycle). (A–D) Weight development 
(A), representative pictures from colonoscopy (original magnification, ×10) and MEICS (B), quantification of colitis severity (C), and representative pictures 
from H&E-stained colon sections (original magnification, ×20) at day 85 (D) reveal that 619W mice show enhanced colitis from the second DSS cycle onward. 
Depicted are mean values and SEM (A–C). Data are representative of 1 of 2 independent experiments with n = 3–6 per experimental group, each experiment. 
(B–D) Each dot represents 1 mouse. Graph in A shows weight development from the same individuals as in B–D. *P < 0.05, **P < 0.01, Kruskal-Wallis test.
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and reduced levels of IL-18 in the colon) in acute and chronic DSS 
colitis, while it was enhanced in 619W mice (Figure 2, A and B).
Cohousing transfers the colitis phenotype from PTPN22–/– and 
619W mice to WT mice. Though the observed changes in inflam-
masome activation and alterations in T cell subsets during colitis 
induction can partially explain the observed differences in colitis 
severity, they cannot explain why presence of the 619W variant in 
PTPN22 is protective during acute colitis, while promoting disease 
severity in chronic DSS colitis. Since aberrant T cell and inflam-
masome activity have both been linked to alterations in the intes-
tinal microbiota, we hypothesized that the intestinal microbiota 
might be involved in the colitis phenotype in our mice. To address 
this, we first performed cohousing studies. When WT mice were 
cohoused with PTPN22–/– littermates after weaning and through-
out the experiment, they showed a disease phenotype similar to 
that of PTPN22–/– counterparts, i.e., increased disease severity 
in acute colitis, but milder disease upon exposure to several DSS 
cycles (Figure 3A). Likewise, cohousing of WT mice with 619W 
mice throughout the experiment resulted in alleviated acute, but 
increased chronic, colitis (Figure 3, A and D), indicating that the 
microbiota at least partially contributes to this phenotype.
Interestingly, cohousing of PTPN22–/– or 619W mice with WT 
mice had no effects on colitis severity (Figure 3, B–D), indicating 
that the phenotype is transferred from PTPN22–/– and 619W mice 
to their WT counterparts but not vice versa. A further indication 
that alterations in microbial composition promote enhanced colitis 
Presence of the 619W variant in PTPN22 results in decreased levels 
of Th1 cells in the inflamed intestine, while promoting Tregs. PTPN22 
negatively regulates molecules in the T cell receptor signaling path-
way (13), and it has been demonstrated that it influences the devel-
opment of Th cell subsets (23). Consistent with previous reports 
(23, 24), we found enhanced levels of regulatory T cells (Tregs) in 
PTPN22–/– mice undergoing acute and chronic DSS colitis (Supple-
mental Figure 2, A and B). Notably, a similar but less pronounced 
phenotype was observed in 619W animals (Supplemental Figure 
2, A and B). This is in line with reports published by Dai et al. and 
Brownlie et al. (22, 23), and indicates that presence of the 619W 
variant has effects similar, with respect to T cell biology, to those of 
a deletion of Ptpn22. Further, we found reduced levels of Th1 cells 
in PTPN22–/– mice in both colitis models, while Th17 cells were not 
affected consistently (Supplemental Figure 2, C and D, and data not 
shown). Induction of effector Th cells was overall low in the DSS 
models, arguing against a prominent role of Th cells in DSS-mediat-
ed colitis (Supplemental Figure 2 and data not shown).
Inflammasome activation is enhanced in the inflamed intestine of 
619W mice. We have previously shown that loss of PTPN22 results 
in decreased NLRP3 inflammasome activation, while presence of 
the 619W variant promotes NLRP3-mediated IL-1β secretion (17, 
25). Therefore, we next addressed whether inflammasome acti-
vation is altered within acute and chronic DSS colitis. Consistent 
with our previous findings, PTPN22–/– mice showed decreased 
inflammasome activity (as observed by reduced IL-1β cleavage 
Figure 2. Presence of the 619W variant in PTPN22 affects inflammasome activation and IL-18 secretion. Colitis was induced in WT, 619W, and PTPN22–/– 
mice by (A) administration of DSS for 7 days; and (B) administration of 4 DSS cycles. Colon pieces were analyzed by Western blot and ELISA for IL-1β and 
IL-18, respectively. Each lane in the Western blot represents 1 individual mouse, and each dot in the graph represents 1 individual. Data are representative of 1 
of 2 independent experiments with n = 3–6 per experimental group. *P < 0.05, **P < 0.01, ***P < 0.001, Kruskal-Wallis test. See complete unedited blots in 
the supplemental material.
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respective WT littermates) and how it develops until week 24 (the 
same age as mice after the chronic DSS experiments). Starting at 
an age of 12 weeks, both PTPN22–/– and 619W mice harbored low-
er microbial richness than WT mice, though effects were overall 
minor (Figure 4A and Supplemental Table 1).
Microbial community composition, in contrast, was clear-
ly distinct between the 3 genotypes, as indicated by trends in 
Bray-Curtis dissimilarity (permutational multivariate ANOVA 
[PERMANOVA], P ≤ 10–4 in 9999 permutations; Figure 4B). These 
in 619W mice upon chronic DSS exposure is the fact that antibiotic 
treatment annulated this effect (Supplemental Figure 3), although 
the initial, more severe disease was still present in PTPN22–/– mice.
Altered microbiota in 619W and PTPN22–/– mice. Having 
observed drastic effects of cohousing and microbiota depletion, 
we next analyzed the composition of the intestinal microbiota in 
the different mouse lines. In a first step we analyzed the micro-
biota in the 3 genotypes at the time of weaning (until that time, 
the PTPN22–/– and 619W mice were housed together with their 
Figure 3. Cohousing transfers the phenotype from 619W and PTPN22–/– mice to WT littermates. (A–C) Chronic colitis was induced in WT mice that were 
cohoused since birth with 619W or PTPN22–/– mice as indicated (A); PTPN22–/– mice that were cohoused since birth and throughout the experiment with 
WT mice, or mice that were housed only with PTPN22–/– mice after weaning and throughout the experiment (B); or 619W mice that were cohoused since 
birth and throughout the experiment with WT mice, or mice that were housed only with 619W mice after weaning and throughout the experiment (C). (D) 
Representative pictures (original magnification, ×10) and scoring of histologic colitis severity in H&E-stained sections of the terminal colon from mice in 
A–C. Data are representative of 1 of 2 independent experiments. Weight curves show mean ± SEM for each group; n = 3 for H2O group and n = 5 for all other 
groups. The other graphs show values and SEM, and each dot represents 1 individual mouse. –/–, PTPN22–/–. *P < 0.05, **P < 0.01, Kruskal-Wallis test.
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characteristically enriched for OTUs classified as Lactobacillus, 
Helicobacter, and Sutterellaceae. Further, WT mice that were not 
separated from their PTPN22–/– or 619W littermates after wean-
ing closely resembled their 619W or PTPN22–/– counterparts. 
This might reflect that the microbiota is transferred between indi-
viduals in the same cage (26).
Changes in microbiota during colitis induction. Given these 
baseline differences, we next assessed the impact of DSS treat-
ment on the microbiota in the different genotypes, testing at 
baseline, after 1 DSS cycle (acute colitis), after a recovery phase of 
10 days, and after 4 repeated DSS cycles (chronic colitis). Micro-
biota community composition was most strongly associated with 
time point (Figure 6; PERMANOVA on Bray-Curtis dissimilarities 
across all time points, genotypes, and treatments; R2 = 0.08) and 
genotype (R2 = 0.063), with both factors dominating DSS treat-
ment (R2 = 0.022) and interaction terms (all terms at P ≤ 10–4 in a 
global PERMANOVA test).
Acute DSS-induced colitis triggered a significant shift in com-
munity composition in all 3 genotypes (Figure 6, A–C; P ≤ 10–4), 
most pronounced in 619W mice (R2 = 0.127) and mildest in WT 
(R2 = 0.089), while characteristically directed for each genotype. 
These shifts were exacerbated during the recovery phase for 619W 
(DSS-treated vs. untreated mice, R2 = 0.205) and PTPN22–/– (R2 = 
0.159) but not in WT mice, with genotypes becoming more com-
positionally dissimilar in treated (R2 = 0.248) and untreated (R2 = 
0.197) mice. This indicates that while WT mice at least partially 
recovered from acute DSS colitis, treatment-induced composi-
tional shifts increased in PTPN22–/– and 619W mice.
After 3 additional DSS cycles (inducing a chronic colitis), 
composition between treatment groups within each genotype 
remained significantly different, but shifts were moderate (P < 
0.05; R2 ≤ 0.05). Interestingly, genotype-associated compositional 
variation was larger in the untreated group (R2 = 0.108) than in the 
DSS group (R2 = 0.512) after 4 DSS cycles, indicating that at least 
some aspects of the compositional response to chronic colitis were 
shared among genotypes.
These trends were surprisingly robust to effects of cohousing 
during the experiment (Figure 6B). As observed in untreated mice 
(Figure 4A), WT mice cohoused with PTPN22–/– or 619W mice after 
weaning were compositionally similar to their respective litter-
mates, but not vice versa. This observation extended to DSS-treated 
mice: WT mice cohoused with PTPN22–/– or 619W mice followed 
the treatment-induced compositional shifts of their counterparts 
at all tested time points. This indicates that the genotype-specific 
compositional response to treatment was transferred to cohoused 
WT mice. As in non-cohoused mice, genotype effects dominated 
over treatment effects (R2 = 0.184 and 0.075, respectively; see also 
clustering along principal coordinates analysis axes 1 and 2 in Figure 
6B, explaining 32.3% and 15.7% variation, respectively).
differences increased with age: while at the time of weaning, gen-
otypes were already compositionally distinct (R2 = 0.284, P ≤ 10–4), 
microbiome maturation was characterized by more pronounced 
and genotype-specific compositional shifts (R2 > 0.6 at later time 
points). WT mice that were cohoused with 619W mice or PTPN22–/– 
mice after weaning developed a microbiota similar to that of 
their 619W or PTPN22–/– littermates. In contrast, PTPN22–/– 
and 619W mice cohoused with WT remained within genotype. 
This indicates that presence of the variant or deletion of PTPN22 
clearly and characteristically influences microbial composition.
A total of 83 operational taxonomic units (OTUs) were dif-
ferentially abundant in PTPN22–/– or 619W mice relative to WT 
baselines at any of the tested time points, representing the core 
murine gut bacterial phyla Bacteroidetes, Firmicutes, Proteobac-
teria, and Deferribacteres (Figure 5 and Supplemental Table 1  
for a full list). While some univariate associations were shared 
between genotypes (e.g., Bacteroides OTU S8307 was enriched 
in both, whereas Lachnospiraceae OTU S56104 was depleted), 
others were genotype-specific; for example, 619W mice were 
Figure 4. 619W and PTPN22–/– genotypes are associated with a dis-
tinct gut microbiota. Relative to matched WT controls, both 619W and 
PTPN22–/– mice showed baseline differences in microbiota taxa richness 
(A) and overall community composition (B; principal coordinates analysis 
[PCoA] of Bray-Curtis dissimilarities) that were conferred to some extent to 
cohoused WT littermates, but not vice versa. See Supplemental Table 1 for 
full data and individual statistical test results.
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Genotype-specific trends in community-level variation were 
mirrored at the level of individual taxa, with a total of 164 OTUs 
across all major gut phyla differentially responding to DSS treatment 
among genotypes across tested time points (Figures 7 and 8 and Sup-
plemental Table 2). In WT mice, acute colitis was associated with 
a depletion of several OTUs classified as Bacteroidales, Clostridi-
ales, and Lactobacillus, accompanied by an enrichment of Erysip-
elotrichales (including Turicibacter sanguinis), Proteobacteria, and 
Mollicutes. Response to chronic colitis was more attenuated, with 
few significantly associated OTUs, in line with the more moderate 
trends in overall community composition.
In PTPN22–/– mice, Akkermansia muciniphila (among other 
OTUs, including Eubacterium and Lactobacillus spp.) were strong-
ly enriched upon acute colitis, but depleted (relative to WT) in 
untreated mice. These associations generally did not persist at the 
recovery and chronic colitis stage, but were replaced by other (and 
fewer) univariate signatures, most prominently a strong enrich-
ment of Flavonifractor spp.
Similarly, individual OTU signatures in 619W mice were 
specific to genotype and time point. Acute DSS colitis trig-
gered a loss of Deferribacterales, Sutterellaceae, Helicobacter, 
and Turicibacter sanguinis, as well as an enrichment of several 
Bacteroidales and Clostridiales OTUs (including the butyrate 
producer Ruminococcaceae spp.). Most of these associations 
did not persist after recovery or during chronic colitis, which 
were characterized by few specific OTUs, and few consistent-
ly differential taxa. In contrast, untreated 619W were enriched 
for Akkermansia muciniphila, Sutterellaceae, and Helicobacter 
relative to WT controls at the recovery and chronic colitis time 
points, but depleted for several OTUs across phyla.
Thus, microbiota signatures in response to DSS treatment 
were highly genotype-specific, at the levels of both entire-commu-
nity composition and the abundance of individual taxa, and each 
genotype showed characteristic changes at each tested experi-
ment time point.
Transfer of microbiota from 619W mice after the first DSS cycle 
leads to enhanced colitis in treatment-naive 619W and WT mice. To 
investigate whether the changes in microbial community after 
recovery from the first DSS cycle might be responsible for the 
altered disease outcome in the later disease course, we trans-
ferred microbiota from mice after recovery from the first cycle 
(day 18) into treatment-naive mice (Figure 9A). Notably, 619W 
mice that received cecum content from 619W mice collected 
at day 18 were no longer protected from acute DSS-induced 
Figure 5. Associations of individual taxa 
with 619W and PTPN22–/– genotypes. 
Operational taxonomic units (OTUs) from 
various taxonomic groups showed distinct 
univariate trends of enrichment or deple-
tion relative to WT controls, concordant or 
discordant between PTPN22–/– and 619W 
genotypes. See Supplemental Table 1 for 
full data and individual statistical test 
results.
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colitis, but showed enhanced disease compared with mice that 
received cecum content from either WT mice at day 18 or treat-
ment-naive 619W mice (Figure 9B). In PTPN22–/– mice, transfer 
of cecum content from PTPN22–/– mice obtained after recovery 
from the first DSS cycle (day 18) was sufficient to transmit the 
milder colitis that was observed in PTPN22–/– mice after sever-
al DSS cycles: PTPN22–/– mice that received stool collected from 
PTPN22–/– mice at day 18 showed decreased colitis severity upon 
DSS treatment compared with those that received cecum con-
tent from naive PTPN22–/– or WT mice at day 18 (Figure 9C). 
Likewise, transfer of cecum content from 619W mice at day 18 
into WT mice promoted disease, while transfer of cecum content 
from WT mice did not affect disease severity and cecum content 
from PTPN22–/– mice resulted in milder disease (Figure 9D).
PTPN22 controls the expression of antimicrobial peptides via 
regulating IL-18 secretion from monocytes/macrophages. PTPN22 is 
exclusively expressed in immune cells; hence we next addressed 
the mechanism of how loss or altered function of PTPN22 might 
affect the composition of the intestinal microbiota. Notably, 
mRNA expression of the antimicrobial proteins (AMPs) Reg3g 
and Defa5 was enhanced in intestinal epithelial cells from WT and 
619W but not PTPN22–/– mice upon acute DSS treatment (Figure 
10A and data not shown). After recovery from the first DSS cycle 
(day 18), however, expression of both of the AMPs decreased in 
619W mice, but not in WT or PTPN22–/– mice, in which expression 
was further enhanced (Figure 10A and data not shown ). Similar 
results were obtained at the end of chronic DSS colitis induction 
(Figure 10A and data not shown).
Figure 6. Genotype-specific effects of DSS treatment on the gut microbiota. (A) Distinct compositional shifts in each genotype relative to H2O-treated 
controls were observed upon 1 cycle of DSS treatment (acute colitis), following a 10-day recovery phase, and upon 4 DSS cycles (chronic colitis). (B) These 
shifts were conferred to WT mice cohoused with PTPN22–/– or 619W mice, but not vice versa. Note that mice in A were not cohoused, whereas in B, WT 
mice were cohoused with PTPN22–/– or 619W, and vice versa. (C) Compositional shifts could be differentially attributed to the factors genotype, treatment, 
and time point, as indicated by R2 values in PERMANOVA tests on data subsets. Note that for illustration purposes, only 1 of several replicate experiments 
is shown in A; the total number of mice per group used in statistical tests is reported on the right and in Supplemental Table 2.
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ent when IL-18 was inhibited (Figure 10C). This strongly indicates 
that PTPN22 affects the expression of AMPs via modulating IL-18 
secretion/signaling.
Discussion
Here we show that PTPN22 crucially affects colitis development, 
and that these effects are — at least in part — due to changes in 
the intestinal microbiota. In line with previous reports, we observe 
increased acute colitis in PTPN22–/– mice (14, 17), while mice car-
rying the autoimmunity-associated PTPN22 619W variant were 
protected from colitis upon acute DSS treatment. This protective 
effect of the variant is well in line with the notion that the variant 
protects from CD onset (6).
Notably, acute DSS colitis lacks a recovery phase. The natu-
ral disease course in IBD patients, however, is often characterized 
by phases of remission with few or no symptoms, intermitted by 
relapses with sometimes severe intestinal inflammation (3). Inter-
estingly, when we subjected our mice to chronic DSS colitis — a 
Monocyte/macrophage-derived IL-18 induces the expression of 
antimicrobial peptides. In order to determine how PTPN22 might 
affect the expression of AMPs, we next cocultured MC-38 intes-
tinal epithelial cells (IECs) with bone marrow–derived macro-
phages (BMDMs) or T cells from WT, PTPN22–/–, or 619W mice. 
To induce production of factors that might influence the secre-
tion of AMPs, we pulsed the BMDMs with MDP and stimulated 
T cells with anti-CD3/CD28 before coculture. Interestingly, 
we observed that coculture with BMDMs from PTPN22–/– mice 
resulted in moderate expression of Reg3g, while coculture with 
BMDMs from 619W mice promoted Reg3g expression (Figure 
10B). On the other hand, coculture with T cells did not affect 
the expression of AMPs (Figure 10B).
It has been reported that IL-18 affects expression/secretion 
of AMPs in the intestine (27). In line with this observation, inhi-
bition of IL-18 resulted in overall decreased induction of AMPs. 
Interestingly, the increase in AMP expression observed upon 
coculture with macrophages from 619W mice was no longer pres-
Figure 7. Univariate associations of individual taxa with genotype and DSS treatment. Average relative abundances (left) and relative fold changes (right) of 
selected taxa associated with genotype and DSS treatment response at various time points. See Supplemental Table 2 for full data on individual associations.
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entially. Both inflammasome activation and altered T cell func-
tion have been reported to affect the intestinal microbiota, which 
might respond differentially in models with recovery.
Our results show that presence of the 619W variant in PTPN22 
affects the composition of the intestinal microbiota per se, but 
even more importantly upon acute or chronic DSS treatment, 
which might crucially contribute to the observed alterations in 
colitis severity (protection in acute, but disease-promoting effects 
in chronic, DSS colitis with recovery phases). Cohousing of WT 
mice with 619W or PTPN22–/– mice showed that the phenotype of 
the PTPN22–/– and the 619W mice is transmissible, possibly medi-
ated by the microbiota.
model with several cycles of acute colitis followed by recovery, 
hence reflecting the varying disease course in IBD patients — mice 
carrying the PTPN22 variant were no longer protected. This is of 
great interest since it is similar to the human situation, in which the 
PTPN22 variant protects from CD onset, but in affected patients, 
presence of the variant does not correlate with a milder disease 
course or fewer complications (28).
When addressing T cell subsets or inflammasome activation, 
we observed phenotypes similar to those previously reported (17, 
23), and moreover, these changes were consistent in acute and 
chronic colitis models, hence these changes alone cannot explain 
why the PTPN22 variant affects acute and chronic colitis differ-
Figure 8. Phylogenetic representation of univariate genotype-specific taxa associations with DSS treatment. Responders to DSS treatment (enrichment 
or depletion) across genotypes and time points were phylogenetically distributed, although some clades showed specific patterns consistent (or discor-
dant) among genotypes (see main text and Figure 7). See Supplemental Table 2 for full data on individual associations.
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producers, such as Lachnospiraceae and Ruminococcaceae, were 
increased in both PTPN22–/– and 619W mice during acute and 
chronic colitis, although disease severity was opposite. Neverthe-
less, some Clostridiales OTUs, which contain important butyrate 
producers, were clearly depleted specifically in 619W mice after 
chronic DSS colitis, possibly contributing to the enhanced colitis 
severity in chronic colitis observed in those mice.
Overall, while shifts in community composition and the 
enrichment or depletion of individual taxa merely correlated with 
genotype and differential treatment responses, the results of our 
transplantation and cohousing experiments provide orthogonal 
evidence suggesting a causal role of the microbiota in mediating 
genotype-specific effects.
Apart from changes in microbiota composition between the 3 
genotypes, we found differences in the expression of AMPs. Notably, 
expression of Rag3g and Defa5 was initially increased in 619W mice, 
but significantly declined after the first recovery phase. Since AMPs 
are important factors to reduce the number of mucosa- adherent, 
potentially pathogenic bacteria (38), this might explain why 619W 
mice display increased disease in later DSS cycles.
AMPs were induced in intestinal epithelial cells upon cocul-
ture with macrophages that were pretreated with the bacterial 
cell wall product MDP, and this was dependent on IL-18 secre-
tion. In line with our previous studies, inflammasome activation 
and IL-18 production are increased in the intestine of 619W 
mice. Further, it has been shown that IL-18 on one hand pro-
motes AMP production (27), but on the other hand also promotes 
goblet cell loss during chronic DSS-induced colitis (39), result-
ing in decreased mucus and AMP production. Hence, enhanced 
IL-18 secretion in mice featuring the 619W variant in PTPN22 
might promote antimicrobial peptide secretion in acute colitis, 
but in the chronic model might promote loss of goblet cells that 
in turn could drive the observed loss of an induction of AMPs 
and subsequently reduced levels of AMPs.
An additional mechanism of how PTPN22 might affect the 
secretion of AMPs is via its role in autophagy. We have shown that 
loss of PTPN22 results in enhanced autophagy (18), and recent 
reports demonstrated that in goblet cells, autophagy is crucial for 
secretion of lysozyme — especially in the presence of pathogen-
ic bacteria (40). Therefore, it might be that PTPN22 affects AMP 
release via regulation of autophagy.
Taken together, our results demonstrate that PTPN22 is an 
important regulator of intestinal health via controlling the com-
position of the intestinal microbiota. Interestingly, induction of 
acute colitis changes the host response toward bacteria in 619W 
mice in a way that finally renders the 619W mice more susceptible 
to colitis induction. This is especially interesting, since it shows 
that the very same genetic variant can have both beneficial and 
disease-driving effects, depending on the timing of insults in the 
intestine. It might also explain why presence of the 619W variant 
protects from onset of CD but does not result in a milder disease 
course in affected patients (28).
Methods
Mice and colitis induction. PTPN22-knockout (PTPN22–/–) mice in the 
C57BL/6 background (13) were initially obtained from A.C. Chan, 
Genentech, San Francisco, California, USA, and crossed with WT C57/
In line with this, we found profound differences within the 
intestinal microbiota, both at basal state and also after recovery 
from the first DSS cycle and after the induction of chronic DSS 
colitis: presence of the 619W variant resulted in increased levels 
of potentially beneficial bacteria upon acute DSS treatment, such 
as OTUs classified as Lactobacillus, and depletion of potential 
pathogens, such as Turicibacter sanguinis, which might explain the 
reduced disease severity at this stage. However, we also observed 
an increase of the potential pathogen Helicobacter at baseline 
and when mice were allowed to recover. However, the role of 
Helicobacter in IBD is controversial, and Helicobacter products 
might also exert antiinflammatory effects (29, 30). In contrast, 
PTPN22–/– mice showed a characteristic increase of Akkermansia 
and Ruminococcacea in acute colitis, which was not observed in 
619W mice, but might account for the robust recovery and sub-
sequent milder disease in later DSS cycles. Notably, Akkermansia 
also slightly increased in 619W mice upon acute DSS treatment, 
but was reduced upon recovery and in chronic colitis.
Akkermansia is a genus of Gram-negative mucus-degrading 
bacteria that has recently received increasing attention: its pres-
ence has been associated with better treatment response and 
recovery from colitis (31), and better treatment response in can-
cer patients treated with checkpoint inhibitors (32). The role of 
Akkermansia in intestinal health is controversial, and it is unclear 
whether its biological roles in the human and murine gut are 
equivalent: while some reports showed that Akkermansia might 
reduce inflammation (33), a recent study showed that presence of 
Akkermansia promotes colitis in IL-10–/– mice (34). Notably, this 
study also showed that defects in IL-18 production in IECs pro-
mote Akkermansia overgrowth, and supplementation of IL-18 was 
sufficient to reduce colitis in their model (34). This is of interest 
since we showed here that PTPN22 is involved in regulating IL-18 
levels in the inflamed intestine. Hence, it might be that changes in 
IL-18 levels as observed in PTPN22–/– and 619W mice are responsi-
ble for the observed changes in Akkermansia abundance.
Another important group of bacteria involved in intestinal 
health are butyrate producers, which are drastically reduced in IBD 
patients (35, 36). Butyrate is an important energy source for IECs 
and promotes wound healing (37), while it dampens proliferation 
in colonic cancer cells (37). This is of interest since some butyrate 
Figure 9. Transfer of stool after the first DSS cycle recapitulates the 
phenotype in chronic colitis. Cecum content was collected from WT, 
PTPN22–/–, and 619W mice that were treated with DSS for 7 days and 
allowed to recover for 10 additional days (= day 18 DSS). Cecum content 
was then transferred into WT, PTPN22–/–, or 619W mice that had been 
treated with an antibiotic cocktail for 1 week to deplete the microbiota. 
(A) Schematic overview of the experimental setup. (B–D) Weight devel-
opment, representative pictures (original magnification, ×10) from H&E-
stained terminal colon sections, and scoring of histological damage of 
619W mice that received cecum content of treatment-naive 619W mice, 
WT mice upon colitis induction, or 619W mice after colitis induction 
(B); PTPN22–/– mice that received cecum content of treatment-naive 
PTPN22–/– mice, WT mice upon colitis induction, or PTPN22–/– mice after 
colitis induction (C); and WT mice that received cecum content of treat-
ment-naive WT mice or WT, 619W, or PTPN22–/– mice after colitis induc-
tion (D). Depicted are mean values and SEM; n = 5 for each experimental 
group. Data are representative of 1 of 2 independent experiments. Abx, 
antibiotic treatment. *P < 0.05, **P < 0.01, Kruskal-Wallis test.
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weaning. For acute DSS colitis induction, 2.5% DSS was supplemented 
to the drinking water for 7 days. For induction of chronic DSS colitis, each 
mouse received 4 cycles of DSS treatment consisting of 7 days with 1.5% 
DSS in the drinking water followed by a 10-day recovery phase with nor-
mal drinking water. After the last DSS cycle, mice received normal drink-
ing water for 4 weeks. For microbiota depletion using antibiotics, mice 
were treated with ampicillin (1 g/l; Sigma-Aldrich), neomycin sulfate 
(1 g/l; Sigma-Aldrich), metronidazole (1 g/l; Sigma-Aldrich), and vanco-
mycin (500 mg/l; Sigma-Aldrich) in the drinking water starting 2 weeks 
before the first DSS cycle (chronic DSS colitis), or for 1 week followed by 3 
days recovery before transfer of cecum content (transplantation studies).
B6 mice (The Jackson Laboratory) to obtain PTPN22+/– mice. A colony 
of PTPN22+/– mice was maintained in our vivarium and crossed with 
each other to obtain PTPN22–/– and WT littermates for experiments. 
Ten- to twelve-week-old female littermate mice were used for all studies. 
C57BL/6 mice carrying the 619W PTPN22 variant (619W mice) (22) were 
obtained from D. Rawlings, University of Washington School of Medi-
cine, Seattle, Washington, USA, and crossed with WT mice to obtain mice 
heterozygous for the 619W allele. These mice were then crossed with 
each other to maintain a colony of mice heterozygous for the 619W allele 
and to obtain 619W and WT littermates for experiments. Unless other-
wise stated, mice were separated according to genotype directly after 
Figure 10. PTPN22 affects expression of antimicrobial peptides in an IL-18–dependent manner. (A) Reg3g mRNA expression in WT, PTPN22–/–, and 619W 
mice after the first DSS cycle (day 8), after recovery (day 18), or at the end of chronic colitis induction (day 85). (B) MC-38 cells were grown on inserts and 
cocultured with MDP-activated bone marrow–derived macrophages (BMDMs) or anti-CD3/CD28–activated T cells from WT, PTPN22–/–, or 619W mice, and 
mRNA levels of Reg3g were analyzed by quantitative PCR. (C and D) MC-38 cells were cocultured with MDP- activated BMDMs from WT, PTPN22–/–, or 
619W mice in the presence of an isotype control or an anti–IL-18 antibody and analyzed for mRNA expression of Reg3g (C) and Defa5 (D). Data are repre-
sentative of 1 of 2 independent experiments. Depicted are mean values and SEM, and each dot represents 1 individual mouse or experimental sample.  
*P < 0.05, **P < 0.01, ***P < 0.001, Kruskal- Wallis test.
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(Thermo Fisher Scientific) using a 26G needle. Total RNA was iso-
lated using RNeasy Mini Kit (Qiagen) with a DNA removal step. RNA 
concentration was assessed by absorbance at 260 and 280 nm. cDNA 
synthesis was performed using a High-Capacity cDNA Reverse Tran-
scription Kit (Thermo Fisher Scientific) following the manufacturer’s 
instructions. Commercially available TaqMan assays (Thermo Fisher 
Scientific) were used for real-time PCR on a Quant Studio 6 flex Ther-
mocycler (Thermo Fisher Scientific).
16S sequencing. Fecal samples were collected at different time 
points and DNA extracted using the PowerLyzer Soil kit (Qiagen, 
Thermo Fisher Scientific) according to the manufacturer’s instruction. 
Targeted amplification using the primer pair T515F × 806R described 
in the Earth Microbiome Project (44) and MiSeq sequencing of the 16S 
rRNA V4 region were performed by Microsynth. Raw sequence data 
are available from the European Nucleotide Archive, project accession 
PRJEB26758. Sample metadata and OTU count tables are available 
as Supplemental Tables 1 and 2. Relevant analysis code is available 
at https://git.embl.de/tschmidt/PTPN22_microbiota. Demultiplexed 
paired-end reads were denoised, merged, and filtered for chimeric 
reads using DADA2 (45). Reads were then mapped to a preclustered 
reference database of full-length 16S rRNA sequences and taxonomi-
cally classified using MAPseq v1.0 (46). Reads that did not confidently 
map to 98% average linkage reference OTUs were aligned to a sec-
ondary-structure-aware bacterial 16S model using Infernal v1.1 (47) 
and hierarchically clustered into 98% average linkage OTUs using 
hpc-clust (48), as described previously (49). In short, we fitted nega-
tive binomial generalized linear models on dispersion-adjusted OTU 
count data, accounting for blocked designs involving repeated inde-
pendent experiments, and conducted likelihood ratio tests on the 
resulting models, followed by test-wise FDR adjustment for multiple 
hypothesis testing with a significance level of FDR < 0.01 (see online 
analysis code for details).
Statistics. Microbiome analyses were conducted using custom 
R scripts, relying on several external packages, including vegan, 
ggplot2, and edgeR. Hill diversities (50) were calculated on OTU 
counts rarefied to 10,000 reads. Community compositional distances 
were calculated as Bray-Curtis dissimilarity on nontransformed and 
sqrt-transformed counts, weighted and unweighted Jaccard distance, 
and weighted and unweighted TINA distances (51). Unless otherwise 
indicated, results are reported for Bray-Curtis dissimilarities on non-
transformed counts, but findings were generally consistent between 
dissimilarity metrics. Differential abundance of individual OTUs was 
detected using edgeR with robust count dispersion estimation, as sim-
ilarly reported previously (52).
For data on mouse and cell culture experiments, data were ana-
lyzed using GraphPad Prism software with the statistical test indicated 
in the respective figure legends. If not otherwise stated, data are pre-
sented as individual dots for each sample/mouse, a line for mean, and 
bars indicating SEM. Tests were always 2-sided where applicable, and 
a P value below 0.05 was considered significant.
Cell culture. To generate BMDMs, bone marrow from WT, 
PTPN22–/–, or 619W mice was incubated for 7 days in DMEM supple-
mented with 10 IU M-CSF (Calbiochem), 10% FCS, and 1% penicillin/
streptomycin solution (Thermo Fisher Scientific). MC-38 cells were 
obtained from ATCC and cultured in DMEM supplemented with 10% 
FCS. For coculture experiments, MC-38 cells (DSMZ) were seeded on 
inserts (Merck Millipore) and grown for 4 days. BMDMs were seeded 
Assessment of colitis severity and histological score. Animals were 
anesthetized i.p. with 90–120 mg/kg body weight ketamine (Vétoqui-
nol) and 8 mg/kg body weight xylazine (Bayer). Animals were exam-
ined as described previously (41). Recording was performed with the 
Karl Storz Tele Pack Pal 20043020 (Karl Storz Endoskope). Colonos-
copy was scored using the murine endoscopic index of colitis severity 
(MEICS) scoring system as described previously (41) using the fol-
lowing 5 parameters: (a) transparency of the colon, (b) changes of the 
vascular pattern, (c) fibrin visible, (d) granularity of the mucosal sur-
face, and (e) stool consistency. Histological scoring for inflammatory 
infiltration and epithelial cell damage was performed on H&E-stained 
sections of the most distal 1 cm of the mouse colon (41, 42).
Single-cell isolation and flow cytometry. Single-cell suspensions 
were generated from spleen, mesenteric lymph nodes, and the colonic 
lamina propria as described previously (43). In brief, spleen and lymph 
nodes were smashed over a 70-μm cell strainer before red cell lysis 
using ACK buffer (1.5M NH4Cl; 100 mM KHC03, 10 mM EDTA). For 
isolation of lamina propria lymphocytes, intestinal tissue pieces were 
incubated for 30 minutes in HBSS supplemented with EDTA (2 nM) 
on a shaker (250 rpm) at 37°C, then vortexed vigorously, and intesti-
nal epithelial cells were washed away with fresh HBSS. Tissue pieces 
were then incubated in digestion solution (RPMI containing 10% FCS, 
2 mg/ml collagenase IV, 4 mg/ml dispase, 0.2 mg/ml DNase I) for 30 
minutes. Cells were passed through a 70-μm strainer, washed with 
PBS, and used for FACS analysis. For intracellular cytokine staining, 
cells were treated with PMA (50 ng/ml; Sigma- Aldrich) and ionomy-
cin (1 μg/ml; Sigma-Aldrich) in the presence of 10 μg/ml brefeldin 
A (Sigma-Aldrich) for 4 hours. Cells were harvested, washed in PBS, 
stained for surface molecules for 15 minutes, washed in FACS buffer 
(PBS, 2% FCS), and fixed in fixation/permeabilization buffer (BD) for 
20 minutes. Cells were washed and resuspended in permeabilization 
buffer (BD) before addition of anti–IFN-γ and anti–IL-17 antibody for 
30 minutes. Before analysis, cells were washed in permeabilization 
buffer and resuspended in FACS buffer. A FACS Canto II or an LSR 
Fortessa from BD was used for all analysis.
Western blotting. Protein was extracted from colon specimens with 
M-PER lysis buffer (Thermo Fisher Scientific) using a GentleMACS 
(Miltenyi) tissue homogenizer. Cells (1 × 106) were lysed in 100 μl 
M-PER using a 26G needle. An aliquot of each lysate was mixed with 
loading buffer (NuPAGE 4× LDS Sample Buffer, Life Technologies) 
and 50 mM DTT and boiled for 5 minutes at 96°C. Proteins were 
separated by SDS-PAGE and transferred onto nitrocellulose mem-
branes (GE Healthcare). Membranes were blocked with 1 % blocking 
solution, and primary antibody (anti–IL-1β: R&D Systems, ordering 
number AF-401-NA; anti–IL-18: Santa Cruz Biotechnology, ordering 
number sc-7954) was added in blocking buffer (3% BSA in washing 
buffer [Tris-buffered saline containing 1% Tween-20]). Membranes 
were washed for 30 minutes, HRP-labeled secondary anti-goat or 
anti-rabbit IgG antibody (Santa Cruz Biotechnology, ordering num-
bers sc-2020 and sc-2004, respectively) in blocking buffer was add-
ed for 30 minutes, and membranes were washed for 30 minutes with 
TBST. Immunoreactive proteins were detected using an ECL detec-
tion kit (Thermo Fisher Scientific). Densitometric analysis of Western 
blots was performed using NIH ImageJ software.
Real-time PCR. Colon tissue was mechanically dissociated and 
lysed in RLT buffer (Thermo Fisher Scientific) using a GentleMACS 
tissue homogenizer (Miltenyi). Cells were disrupted in RLT buffer 
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